Mike Gorenstein

Cronos CEO Mike Gorenstein Says He's Optimistic About Trump's Impact On Cannabis
Cronos Cannabis Co. Reports 38% YOY Increase In Q3 Revenue, Boosts International Sales
Highest On Record - Cronos Group Reports 46% YoY Increase In Q2 Net Revenue
Cronos Cannabis Co. Reports 38% YOY Increase In Q3 Revenue, Boosts International Sales
Highest On Record - Cronos Group Reports 46% YoY Increase In Q2 Net Revenue
Cronos' New Cannabis Products To Help You Breeze Through Summer
Cronos Cannabis Co. Will Provide $51M To GrowCo Toward Facility Expansion Fund

Mike Gorenstein Recent News

Marijuana Company Cronos Reduces FY23 Net Loss As It Utilizes Global Expansion
Canadian Cannabis Co. Cronos Explores Untapped Potential In Australia's Marijuana Industry
Group announced on Tuesday that it is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited. The Toronto-based company owns roughly 10% of Vitura's common shares, formerly known as Cronos Australia, and will supply cannabis for Vitura.
Multi-Million Dollar Cannabis Campus Sale To Help Canadian Pot Producer Pursue Organic Growth
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced on Monday that its wholly-owned subsidiary entered into an agreement with Future Farmco Canada Inc., a vertical farming company, for the sale and leaseback of its Ontario, Cananda-based property.
Products With This Rare Weed Compound Hit Shelves In Three Canadian Provinces And More
As the top US cannabis market, California is witnessing an influx of THCV products, some of the top-selling Canadian provinces are getting in on it, too.
Cronos Exits US Hemp CBD Market, But Doesn't Give Up On Lord Jones Brand Just Yet
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) is exiting its existing U.S. hemp-derived CBD-focused operations by the end of the second quarter of 2023.
Cronos Q1 2023 Revenue Declines 19.5% YoY, Provides Outlook
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON), released its 2023 first quarter business results, revealing net revenue of $20.1 million, a decrease of 19.5% compared to $25 million in Q1 2022.
Cronos Releases Cannabinoid Life Cycle Study Highlighting Its Sustainable Fermentation Practices
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) in honor of Earth Day, released a Sustainability Study, which outlines the benefits of using fermentation manufacturing methods for cannabinoid production over the impact of traditional methods of cannabis extraction, which levera
Maximize Your Returns: Get To Know The Top Performing Cannabis Stocks Of The Last 12 Months
The past 12 months have been a wild ride for both investors and cannabis shareholders, as evidenced by big rallies as well as steep declines.
Cronos Q4 2022 Revenue Declines 11% YoY, What About Net Loss?
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) net revenue in 2022 was $91.9 million, a 23% increase compared to $74.4 million in 2021. Q4 2022 Financial Highlights
Meet Ivy League-Trained Lawyer Leading The Way In Cannabis Industry: Mike Gorenstein Of The Cronos Group
After the overwhelming success of last year's Benzinga Cannabis Capital Conference, the team is returning to Florida April 11-12, 2023 with awesome events simultaneously taking place on two stages at Miami Beach's historic
Cronos Launches Spinach FEELZ Day Trip Gummies With THC And CBC
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) launched a CBC-focused product, the Spinach FEELZ THC+CBC Day Trip Mango Lime gummies, utilizing Ginkgo Bioworks’ platform for organism design and development.
Key Cannabis Exec Changes You Need To Know About: Who's Florida's New MMJ Czar & More Industry Appointments
Florida Gets New MMJ Czar Florida Department of Health’s officials recently revealed that Christopher Phillip Kimball agreed to serve as the state’s Office of Medical Marijuana Use, succeeding Chris Ferguson, who served for the past three years.
Cronos Q3 Revenue Stagnates, Remains On Track For $20M In Operating Expense Savings
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) Q3 2022 net revenue was $20.9 million, a 2.5% increase compared to $20.4 million in Q3 2021.
Cronos Q2 2022 Revenue Grows 47% YoY, Company Focused On Rare Cannabinoids
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) released its 2022 second quarter business results, revealing gross profit of $4.1 million in Q2 2022 improved by $19.9 million from Q2 2021.
Cronos Partners With Geocann To Launch CBD Gel Capsules By Lord Jones Utilizing VESIsorb For Faster Absorption
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) launched the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the VESIsorb delivery system.
Cronos Q1 Revenue Improves 101.61% YoY, Cannabis Company Attributes Growth To This
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) reported Tuesday its 2022 first quarter business results with net revenue growth of 101.61% year-over-year, due to the revenue improvements in the Israeli medical market and the Canadian adult-use market.
Cronos Group's Mike Gorenstein Returns As CEO
Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced that the board of directors has appointed Mike Gorenstein as chairman, president, and CEO, effective March 21, 2022,
Cannabis Producer Cronos Plunges On $107M Loss, Says Pricing Pressures Drove Write-Downs
Cronos Group (NASDAQ: CRON) opened Thursday morning at $6.62 a share, but quickly lost ground on the heels of an earnings report showing a second-quarter net loss of $107 million.
Cronos CEO Talks Vaping With Cramer
Cronos Group Trades Higher After Revenue Jumps Three-Fold In Q2
Cronos To Acquire 4 Redwood Subsidiaries, Expand Growth In US CBD Market
Cronos Group Will Acquire GMP Compliant Fermentation, Manufacturing Facility
Cronos Group Names Todd Abraham As New Chief Innovation Officer

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved